公开(公告)号：EP1778206A4

公开(公告)日：2009-08-05

申请号：EP05806407

申请日：2005-08-22

申请人： UNIV MICHIGAN

发明人： WANG SHAOMENG ,  WANG GUOPING ,  TANG GUOZHI ,  WANG RENXIAO ,  NIKOLOVSKA-COLESKA ZANETA ,  WANG DAJON ,  XU LIANG

IPC分类号： A61K31/075 ,  A61K31/47 ,  A61K31/495 ,  A61K31/5375 ,  C07C43/02 ,  C07D217/00 ,  C07D413/02

CPC分类号： C07D217/00 ,  C07C43/02 ,  C07D413/02

公开(公告)号：EP1888531A2

公开(公告)日：2008-02-20

申请号：EP06784680.8

申请日：2006-06-08

申请人： SMITHKLINE BEECHAM CORPORATION

发明人： DUFFY, Kevin, J. ,  FITCH, Duke, M. ,  NORTON, Beth, A.

IPC分类号： C07D217/00 ,  C07D277/04 ,  A01N43/52 ,  A61K31/47

CPC分类号： C07D417/06

摘要： Invented is the compound (5Z)-5-(6-quinoxalinylmethylidene)-2-[(2,6-dichlorophenyl)amino]-1,3-thiazol-4(5H)-one, and/or pharmaceutically acceptable salts, hydrates, solvates and pro-drugs thereof. Also invented are pharmaceutical compositions containing this compound, methods of preparing this compound and pharmaceutically acceptable salts, hydrates, solvates and pro-drugs thereof. Also invented are methods of using this compound as an inhibitor of hYAK3 proteins.

摘要翻译： 本发明化合物（5Z）-5-（6-喹喔啉基亚甲基）-2 - [（2,6-二氯苯基）氨基] -1,3-噻唑-4（5H） - 酮和/或其药学上可接受的盐，水合物 ，溶剂化物和前药。 还发明了含有该化合物的药物组合物，制备该化合物及其药学上可接受的盐，水合物，溶剂化物和前药的方法。 还发明了使用该化合物作为hYAK3蛋白抑制剂的方法。

公开(公告)号：EP1814550A2

公开(公告)日：2007-08-08

申请号：EP05818494.6

申请日：2005-10-12

申请人： Bristol-Myers Squibb Company

发明人： SHER, Philip, M. ,  WU, Gang ,  EWING, William, R.

IPC分类号： A61K31/445 ,  A61K31/535 ,  C07D211/26 ,  C07D215/00 ,  C07D217/00 ,  C07D401/12 ,  C07D413/12 ,  C07D419/12

CPC分类号： C07D401/12 ,  C07D211/96 ,  C07D409/12

摘要： The present application describes compounds according to Formula (I), wherein R1, R2, R3, R4, X and Y are described herein. Additionally, the present application describes pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents. Finally, the present application describes methods of treatment using the compounds according to Formula (I) both alone and in combination with one or more additional therapeutic agents.

公开(公告)号：EP1773774A2

公开(公告)日：2007-04-18

申请号：EP05774700.8

申请日：2005-07-26

申请人： Merck & Co., Inc.

发明人： PINKERTON, Anthony, B. ,  VERNIER, Jean-Michel ,  CUBE, Rowena, V. ,  HUTCHINSON, John, H. ,  HUANG, Dehua ,  BONNEFOUS, Celine ,  GOVAK, Steven, P. ,  KAMENECKA, Theodore

IPC分类号： C07D213/02 ,  C07D215/00 ,  C07D217/00 ,  A61K31/44 ,  A61K31/47

CPC分类号： C07D311/16 ,  C07C45/71 ,  C07C49/84 ,  C07C69/734 ,  C07C69/92 ,  C07C217/76 ,  C07C217/92 ,  C07C235/42 ,  C07C255/54 ,  C07C323/12 ,  C07D205/04 ,  C07D209/08 ,  C07D213/30 ,  C07D213/53 ,  C07D213/64 ,  C07D213/65 ,  C07D213/68 ,  C07D213/70 ,  C07D213/71 ,  C07D213/74 ,  C07D213/84 ,  C07D213/89 ,  C07D215/20 ,  C07D217/02 ,  C07D231/56 ,  C07D233/20 ,  C07D233/60 ,  C07D235/06 ,  C07D235/08 ,  C07D235/10 ,  C07D235/16 ,  C07D235/18 ,  C07D239/34 ,  C07D257/04 ,  C07D263/58 ,  C07D271/10 ,  C07D277/74 ,  C07D307/80 ,  C07D311/22 ,  C07D311/24 ,  C07D311/58 ,  C07D401/04 ,  C07D417/04 ,  C07D471/04 ,  C07D473/38

摘要： The present invention is directed to compounds which are potentiators of metabotropic glutamate receptors, including the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

公开(公告)号：EP1466506A4

公开(公告)日：2007-03-07

申请号：EP01991428

申请日：2001-12-26

申请人： DU PONT

发明人： PETROV VIACHESLAV A ,  WANG YING ,  GRUSHIN VLADIMIR

IPC分类号： H01L51/50 ,  C07D213/02 ,  C07D213/26 ,  C07D213/30 ,  C07D213/61 ,  C07D213/68 ,  C07D215/00 ,  C07D215/04 ,  C07D215/12 ,  C07D217/00 ,  C07D239/02 ,  C07D239/26 ,  C07F15/00 ,  C09K11/06 ,  H01L51/00 ,  H01L51/30 ,  H05B20060101 ,  H05B33/12 ,  H05B33/14 ,  H05B33/22

CPC分类号： C07D213/30 ,  C07D213/26 ,  C07D213/61 ,  C07D213/68 ,  C07D215/04 ,  C07D239/26 ,  C07F15/0033 ,  C09K11/06 ,  C09K2211/1007 ,  C09K2211/1029 ,  C09K2211/185 ,  H01L51/0059 ,  H01L51/0081 ,  H01L51/0085 ,  H01L51/5016 ,  H05B33/14

摘要： The present invention is generally directed to electroluminescent Ir(III) compounds, the substituted 2-phenylpyridines, phenylpyrimidines, and phenylquinolines that are used to make the Ir(III) compounds, and devices that are made with the Ir(III) compounds

公开(公告)号：EP1667976A1

公开(公告)日：2006-06-14

申请号：EP04784368.5

申请日：2004-09-17

申请人： Merck & Co., Inc.

发明人： DINSMORE, Christopher, J. ,  BERGMAN, Jeffrey, M. ,  MCINTYRE, Charles, J. ,  ISAACS, Richard ,  CLAREMON, David, A.

IPC分类号： C07D217/00 ,  C07D401/04 ,  A61K31/44

CPC分类号： C07D401/04 ,  C07D217/24 ,  C07D401/06

摘要： The present invention relates to compounds having the structure (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.

公开(公告)号：EP1032559A4

公开(公告)日：2005-05-25

申请号：EP98945914

申请日：1998-09-04

申请人： AVENTIS PHARMA INC

发明人： KOSLEY RAYMOND W JR ,  PALERMO MARK G ,  SHIMSHOCK STEPHEN J ,  WOLF VERONICA

IPC分类号： C07D295/08 ,  A61K31/137 ,  A61K31/216 ,  A61K31/27 ,  A61K31/33 ,  A61K31/382 ,  A61K31/40 ,  A61K31/4402 ,  A61K31/4406 ,  A61K31/4409 ,  A61K31/4427 ,  A61K31/4433 ,  A61K31/4453 ,  A61K31/4535 ,  A61K31/472 ,  A61K31/495 ,  A61K31/496 ,  A61K31/497 ,  A61K31/506 ,  A61K31/5375 ,  A61K31/5377 ,  A61P25/28 ,  C07C69/712 ,  C07C213/02 ,  C07C217/58 ,  C07C217/60 ,  C07C271/44 ,  C07C309/66 ,  C07C309/73 ,  C07D213/74 ,  C07D213/76 ,  C07D213/77 ,  C07D215/38 ,  C07D217/00 ,  C07D217/04 ,  C07D217/26 ,  C07D233/48 ,  C07D239/42 ,  C07D295/096 ,  C07D295/112 ,  C07D295/155 ,  C07D335/02 ,  C07D401/12 ,  C07D409/12 ,  C07F7/18 ,  C07D207/06

CPC分类号： C07D213/74 ,  C07C69/712 ,  C07C217/58 ,  C07C217/60 ,  C07C309/73 ,  C07C2601/14 ,  C07D213/77 ,  C07D215/38 ,  C07D295/096 ,  C07D295/112 ,  C07D295/155 ,  C07D335/02 ,  C07D409/12 ,  C07F7/1852 ,  C07F7/1856

公开(公告)号：EP1487795A4

公开(公告)日：2005-02-09

申请号：EP02775823

申请日：2002-09-12

申请人： ANORMED INC

发明人： MCEACHERN ERNEST J ,  BRIDGER GARY J ,  SKUPINSKA KRYSTYNA A ,  SKERLJ RENATO T

IPC分类号： C12P17/12 ,  C07D215/06 ,  C07D215/20 ,  C07D215/38 ,  C07D215/40 ,  C07D215/42 ,  C07D215/44 ,  C07D215/48 ,  C07D217/02 ,  C07D221/04 ,  C07D241/40 ,  C07D241/42 ,  C07D307/79 ,  C07D491/04 ,  C07D491/052 ,  C07D215/00 ,  C07D217/00 ,  C07D217/22

CPC分类号： C07D217/22 ,  C07D215/06 ,  C07D215/20 ,  C07D215/38 ,  C07D215/40 ,  C07D215/42 ,  C07D215/48 ,  C07D221/04 ,  C07D241/42 ,  C07D307/79 ,  C07D491/04

摘要： This invention describes various processes for synthesis and resolution of racemic amino-substituted fused bicyclic ring systems. One process utilizes selective hydrogenation of an amino-substituted fused bicyclic aromatic ring system. An alternative process prepares the racemic amino-substituted fused bicyclic ring system via nitrosation. In addition, the present invention describes the enzymatic resolution of a racemic mixture to produce the (R)- and (S)- forms of amino-substituted fused bicyclic rings as well as a racemization process to recycle the unpreferred enantioner. Further provided by this invention is an asymmetric synthesis of the (R)- or (S)- enantioner of primary amino-substituted fused bicyclic ring systems.

公开(公告)号：EP1444209A2

公开(公告)日：2004-08-11

申请号：EP02799174.4

申请日：2002-11-01

申请人： Merck & Co., Inc.

发明人： FRALEY, Mark, E. ,  HOFFMAN, William, F.

IPC分类号： C07D239/88 ,  C07D215/00 ,  C07D217/00 ,  A61K31/47 ,  A61K31/517 ,  A61P35/00

CPC分类号： C07D239/88 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/06 ,  C07D403/14 ,  C07D471/04 ,  C07D487/10

摘要： The present invention relates to quinazolinone compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.

公开(公告)号：EP1392280A2

公开(公告)日：2004-03-03

申请号：EP02734382.1

申请日：2002-05-10

申请人： Abbott GmbH & Co. KG ,  WARNER-LAMBERT COMPANY

发明人： KNOBELSDORF, James ,  HAYS, Sheryl ,  STANKOVIC, Charles, J. ,  PARA, Kimberly, S. ,  CONNOLLY, Michael, K. ,  GALATSIS, Paul ,  HARTER, William ,  SHAHRIPOR, Aurash, B. ,  PLUMMER, Mark, Stephen ,  LUNNEY, Beth ,  JANSSEN, Bernd ,  FELL, Jay, Bradford

IPC分类号： A61K31/24 ,  A61K31/195 ,  A61K31/47 ,  A61K31/415 ,  A61K31/44 ,  A61K31/425 ,  A61K31/495 ,  A61K31/50 ,  A61K31/40 ,  A61K31/445 ,  A61K31/535 ,  A61P29/00 ,  A61P25/28 ,  C07C321/00 ,  C07C317/00 ,  C07D207/00 ,  C07D211/06 ,  C07D215/36 ,  C07D217/00 ,  C07D231/56 ,  C07D235/00

CPC分类号： C07D235/06 ,  C07C311/29 ,  C07C311/42 ,  C07C311/46 ,  C07C311/47 ,  C07C335/18 ,  C07C2603/74 ,  C07D217/16 ,  C07D405/12 ,  C07D417/04 ,  C07D417/14

摘要： Novel arylsulfonamide ether compounds and pharmaceutical compositions thereof are described. The use of the novel arylsulfonamide ether compounds and pharmaceutical compositions thereof as inhibitors of interleukin-1β converting enzyme and other cysteine proteases in the ICE family is also described. In addition, methods of treating stroke, inflammatory diseases, septic shock, repurfusion injury, Alzheimer's disease, and shigellosis using a compound of the invention or a pharmaceutical composition thereof are described.